Jeffrey D Capello
CIK 1224108 · EVP & Chief Financial Officer · last filed 2026-10-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BSX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
620 LESHER PLACE
LANSING, MI 48912
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NEOG | Director | 42,306 | $12.21 | $516.6K | $100.2K | 11 | 2026-10-02 |
| AGIO | Director | 10,865 | $36.85 | $400.4K | $0 | 7 | 2026-06-23 |
| BIIB | EVP & Chief Financial Officer | 3,118 | $252.26 | $786.5K | $0 | 5 | 2020-02-14 |
| Tempest Therapeutics, Inc. (OVAS) Delisted | Director | — | — | — | $0 | 5 | 2018-07-06 |
| Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Director | — | — | — | $0 | 3 | 2017-07-27 |
| BSX | EVP & Chief Financial Officer | 447 | $45.58 | $20.4K | -$12.60M | 30 | 2013-12-02 |
| REVVITY, INC. (PKI) Delisted | SVP & CFO | 91,428 | $115.24 | $10.54M | -$989.9K | 4 | 2008-01-31 |
Recent Filings · Page 4 of 7
67 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-12-02 | BSX | Sell (S) | −108,595 | -$1.27M | EDGAR |
| 2013-11-27 | BSX | Mixed | −38,405 | -$709.6K | EDGAR |
| 2013-11-26 | BSX | Mixed | — | -$1.72M | EDGAR |
| 2013-09-03 | BSX | Mixed | −50,000 | -$2.09M | EDGAR |
| 2013-06-18 | BSX | Mixed | +8,358 | -$60.0K | EDGAR |
| 2013-06-11 | Tempest Therapeutics, Inc. (OVAS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-05-14 | BSX | Mixed | +4,876 | -$19.9K | EDGAR |
| 2013-03-20 | — | Buy (P) | +11,111 | $100.0K | |
| 2013-03-04 | BSX | Mixed | +7,059 | -$25.2K | EDGAR |
| 2013-03-01 | BSX | Mixed | +12,342 | -$43.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.